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INTRODUCTION
Gastric cancer is the fourth most common cancer and the sec-
ond leading cause of cancer-related deaths worldwide (1). Surgical
resection for gastric cancer is the only therapeutic modality for
cure (2), and regional lymphadenectomy is recommended as part
of radical gastrectomy (3). Laparoscopic gastrectomy is an emerg-
ing surgical approach that offers significant advantages with re-
spect to short - term outcomes, such as less postoperative pain,
earlier postoperative recovery of gastrointestinal function and
ability to move, and shorter postoperative hospital stay, when
compared with open gastrectomy. Recently, laparoscopic surgery
has come to be regarded as the treatment of choice for early gastric
cancer (EGC), but the indications and outcomes of laparoscopic
gastrectomy for advanced gastric cancer (AGC) are still contro-
versial due to its technical difficulties and the lack of long-term
results. The purpose of this study was to evaluate the oncologic
outcomes of laparoscopic distal gastrectomy (LDG) for AGC.
METHODS
Patients
Between April 2003 and March 2014, laparoscopic distal gas-
trectomy (LDG) was performed for 392 patients with gastric can-
cer, 91 (23.2%) of those were histopathologically diagnosed as AGC
beyond T2 depth. The clinicopathological features, postoperative
outcomes, mortality, morbidity, recurrence, and survival of the pa-
tients who underwent LDG for AGC were reviewed retrospectively.
The eligibility criteria for LDG in our hospital are cT1-3N0-1
(Union Internationale Contre le Cancer 7th edition (4)) gastric can-
cer in the lower or middle body of the stomach. In the case of cT2-
3N1 gastric cancer, D2 lymphadenectomy was performed. All
patients were informed that LDG is regarded as experimental treat-
ment by the Japanese gastric cancer treatment guideline (5), and
a written, informed consent was obtained from all patients. Patient
anonymity should be preserved.
In our hospital, laparoscopic surgery for gastric cancer was in-
troduced in April, 2003, and the indication for LDG for gastric can-
cer was cT1N0 according to the 6th edition of the UICC staging
criteria (6). Laparoscopy-assisted distal gastrectomy (LADG),
which means reconstruction under minilaparotomy, was performed.
We extended the indication to cT3N1 based on development of
the operative procedures with D2 lymphadenectomy, and performed
totally laparoscopic gastrectomy, which included intracorporeal an-
astomosis, from April, 2012. If the tumor depth was obviously
beyond T4, LDG was converted to open surgery. In the case of
suspicious T4 depth, washing cytology was performed twice (just
after laparotomy and before closure the wound) during the sur-
gery and evaluated postoperatively.
Gastrointestinal fiberscopy, barium fluoroscopy, and contrast -
enhanced computed tomography were performed for preopera-
tive staging. All patients provided their written, informed consent.
Data obtained for each patient included the followings : age, sex,
body mass index (BMI), histological type, tumor invasion (T stage),
nodal status (N stage), gastric cancer stage classified according
to the 7th edition of the UICC staging criteria, postoperative out-
comes, postoperative morbidity, recurrences, adjuvant therapy,
and survival. The classification of lymph node dissection was done
according to the 2014 Japanese gastric cancer treatment guide-
lines (ver.4) (5). All values are expressed as meansstandard de-
viations.
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Surgery
All patients were placed in the lithotomy position under general
anesthesia. The surgeon stood on the patient’s left, with the first
assistant on the patient’s right and the camera assistant between
the patient’s legs. Routinely, an umbilical trocar (12 mm) was in-
serted using the open method. Carbon dioxide pneumoperitoneum
was created through the umbilical port, and the pressure was main-
tained around 10 mmHg. A 10-mm flexible laparoscope was then
introduced through the umbilical port. Under laparoscopic guid-
ance, five trocars were introduced, consisting of bilateral subcostal
(5 mm), bilateral mid-abdominal (12 mm), and epigastric (5 mm)
ports.
First, the gastrocolic ligament was divided at the mid position
of the transverse colon about 5 cm from the gastroepiploic arcade
toward the lower pole of the spleen using laparosonic coagulating
shears (LCS).
Next, the right gastrocolic ligament and lymph nodes were dis-
sected along the right gastroepiploic vessels (No.4d). The infrapy-
loric nodes (No.6) and the nodes along the superior mesenteric
vein (No.14v) were dissected. A gauze was placed on the common
hepatic artery, and the hepatogastric ligament was cut using LCS
toward the esophagogastric junction on this gauze, and the right
crus was revealed. After the suprapyloric nodes along the right
gastric vessels (No.5) and the nodes along the proper hepatic
artery (No.12a) were dissected, the duodenum just distal to the
pyloric ring was transected by a linear stapler. Then, the nodes
along the common hepatic artery (No.8a) and the proximal splenic
artery (No.11p) were dissected. The left gastric vein and artery
were cut. After dissecting the nodes along the left gastric artery
(No.7) and the nodes around the celiac artery (No.9), dissection
of the right cardial nodes (No.1) and the nodes along the lesser
curvature (No.3a) was performed. Billrothgastroduodenostomy
or Billrothgastrojejunostomy reconstruction was performed to-
tally under laparoscopy, using flexible laparoscopic stapling de-
vices. Finally, the resected specimen in the collection bag was
removed from the umbilical port, which was extended 3 cm.
Postoperative treatment and follow up
In AGC cases with stages beyond stage, adjuvant chemother-
apy with S-1 alone for 33 cases (7) and S-1 and cisplatin for 4 cases
(8-9) was performed.
Adjuvant chemotherapy was to be started within 4 to 8 weeks
after surgery, following sufficient recovery from the intervention.
All patients were followed according to an established protocol in
our hospital, which includes medical history, physical examination,
and laboratory studies, such as tumor markers. Multi -Detector
CT examinations was performed every 3-6 months, and gastro-
intestinal fiberscopy was performed annually.
Complications
Morbidity was classified according to the revised version of the
Clavien-Dindo classification suggested by Dindo et al. (10).
Statistical analyses
All results were presented as nearSD and analyzed with the
log-rank test. P-value of 0.05 or less was considered significant.
All statistical analyses were performed using Stat View version
5.0 for Windows (SAS Institute Inc., Cary, NC)
RESULTS
Clinicopathological characteristics
The clinicopathological characteristics of the patients are pre-
sented in Table 1. The mean age was 69.211.2 years (range, 38-88
years). Of the 91 patients who underwent LDG, 66 were men
(72.5%), and 25 were women (27.4%). The mean body mass index
was 23.33.4 kg/m2 (range, 14.0-33.2 kg/m2). The most common
histologic type was poorly differentiated adenocarcinoma (50.5%).
The TNM stages (UICC, 7th edition) were : stageB in 26 (28.5%)
patients ;A in 20 (21.9%) ;B in 18 (19.7%) ;A in 13 (14.2%) ;
B in 6 (6.5%) ;C in 6 (6.5%) ; andin 2 (2.1%). Two patients
were in stagedue to liver metastases and peritoneal dissemi-
nation. Liver metastasis, which was very small, was first found in-
traoperatively and gastrectomy was performed to control tumor
bleeding. Peritoneal dissemination, which existed only around
the tumor, was not detected with intraoperative rapid histological
examination and was found postoperatively.
Postoperative Outcomes
For all 91 patients, the mean operation time was 177.226.4 min
(range, 119-258 min), and the mean estimated blood loss was
15.245.8 ml. A total of 59 patients (64.8%) received over D2 dis-
section according to the 2014 Japanese gastric cancer treatment
guidelines (ver.4) (5). The mean number of retrieved lymph nodes
during LDG was 31.414.7. The most frequent type of reconstruc-
tion was Billroth(64.8%). Conversion to open surgery was done
in one patient (1.0%), as a result of suspected T4 wall invasion.
Table 1. Clinicopathological features of patients undergoing LDG
No. patient 91
Age, years, meanSD 69.211.2
Sex, M : F 66 : 25
Body mass index, kg/m2, meanSD 23.33.4
Histologic type
Papillary 2 (2.1%)
Well differentiated 18 (19.7%)
Moderately differentiated 20 (21.9%)
Poorly differentiated 46 (50.5%)
Signet ring cell 2 (2.1%)
Mucinous 2 (2.1%)
Others 1 (1.0%)
Tumor invasion*
T2 (MP) 36 (39.5%)
T3 (SS) 34 (37.3%)
T4a (SE) 21 (23.0%)
Nodal status*
pN0 47 (51.6%)
pN1 17 (18.6%)
pN2 15 (16.4%)
pN3 12 (13.1%)
Tumor staging*
B 26 (28.5%)
A 20 (21.9%)
B 18 (19.7%)
A 13 (14.2%)
B 6 (6.5%)
C 6 (6.5%)
 2 (2.1%)
Where appropriate, data are given as meansSD or as numbers of pa-
tients with percentages given in parentheses.
*According to the 7th edition of the TNM classification.
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Radicality of the operation was R0 in 97.8%, R1 in 1.0%, and R2 in
1.0%. The R1 operation was decided because of peritoneal dissemi-
nation revealed by pathological examination postoperatively, and
the R2 case was due to liver metastases (patient in stage). The
mean postoperative hospital stay was 12.020.2 days (range, 6-
177) (Table 2). There were 14 postoperative complications (15.3%),
and no surgery-related deaths occurred (Table 3). Most compli-
cations could be treated conservatively, but complications beyond
Clavien-Dindo classification gradeoccurred in three cases.
Gradea was duodenal stump leakage, which was successfully
treated by single drainage. Gradea complications were anasto-
motic leakage and pancreatic fistula, which required reoperation
and intensive care for 34 days and 39 days respectively.
Follow-up Results
The median follow-up period was 24.5 months (range, 0.3 -114
months). Tumor recurrence was detected in 10 patients (10.9%)
during follow-up. The sites of recurrences are shown in Fig 1. Liver
metastasis occurred in five patients (stageB, two patients ; stage
A, one patient ; stageC, two patients), peritoneal dissemina-
tion in four patients (stageA, one patient ; stageB, one pa-
tient ; stageC, two patients), paraaortic lymph node metastasis
in three patients (stageA, two patients ; stageC, one patient),
lung metastasis in one patient (stageC), and ovarian metastasis
in one patient (stageB) (there is some overlap). There were no
recurrences in regional lymph nodes around the stomach.
In AGC cases with stages beyond stage, adjuvant chemother-
apy based on S-1 or other drugs was given (Table 4). The most
common regimen was S-1 alone (76.7%). S-1/cisplatin was given
for the patients with stageand stagewith extensive lymph
node metastasis, S-1/docetaxel was given for the patients with
stageas clinical trial. Other patients didn’t received adjuvant
chemotherapy for advanced age, postoperative complications
(Clavien-Dindo classification gradea ), renal dysfunction and
Table 2. Postoperative outcomes
Operation time (min) 177.226.4
Estimated blood loss (mL) 15.245.8
Lymph node retrieved (n) 31.414.7
Degree of lymph node dissection* (n)
D1 12 (13.1%)
D1+ 20 (21.9%)
D2 59 (64.8%)
Conversion to open surgery (n) 1 (1.0%)
Combined with other organ resection 0
Type of reconstruction
Billroth 59 (64.8%)
Billroth 20 (21.9%)
Roux-en-Y 12 (13.1%)
LADG : LDG 53 : 38
Radicality
R0 89 (97.8%)
R1 1 (1.0%)
R2 1 (1.0%)
Postoperative complications, n 14 (15.3%)
Postoperative hospital stay, days 12.020.2
Where appropriate, data are given as meanSD or numbers of patients
with percentages given in parentheses.
LADG Laparoscopy-assisted distal gastrectomy LDG Laparoscopic dis-
tal gastrectomy.
*According to the 2014 Japanese gastric cancer treatment guidelines
(ver.4).
Table 3. Postoperative morbidity
Complications n ?
Grade*
Delirium 3 3.3
Dumping syndrome 1 1.1
Grade*
Surgical Site Infection 1 1.1
Urinary tract infection 1 1.1
Drug rash 1 1.1
Aspiration pneumonia 2 2.2
Anastomotic stricture 2 2.2
Gradea*
Duodenal stump leakage 1 1.1
Gradea*
Anastomotic leakage 1 1.1
Pancreatic fistula 1 1.1
Total 14 15.4
Where appropriate, data show the numbers of patients, with percent-
ages.
*According to the Clavien-Dindo classification.
Fig 1. Sites of recurrence
There is some overlapping.
Table 4. Adjuvant therapy
Initial chemotherapy regimen n ?
S-1 33 76.7
S-1+cisplatin 4 9.3
S-1+docetaxel 2 4.6
Others 4 9.3
CPT-11/CDDP 1 2.3
UFT 1 2.3
5 -FU (oral) 1 2.3
Docetaxel 1 2.3
Total 43
Where appropriate, data show the number of patients, with percentages.
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patients’ hope.
During this observation period, ten patients died, including six
cancer deaths (stageB, one patient ; stageA, two patients ;
stageB, one patient ; stageC, two patients).
According to TNM stage, the overall 5 -year OS and DFS rates
were 92.3% and 91.8% with stageB, 85.4% and 85.4% with stage,
and 49.3% and 26.9% with stage, respectively (Fig. 2). Since the
two patients with stagehad not yet been followed for over one
year, OS or DFS could not be calculated for these patients.
DISCUSSION
Since LADG for EGC was first performed in 1991 and first re-
ported in 1994 (11), improvements in instruments and laparoscopic
technique have allowed for widespread acceptance (12-13). The
laparoscopic approach is used in approximately 39% of gastric
cancer surgeries in Japan (14). This approach offers important
advantages when compared with open surgery, such as a better cos-
metic effect, improved quality of life, less intense pain, shortened
hospital stay, early rehabilitation, and early return to social activity
(15-17). The safety of LADG for clinical stagecancers (including
patients with T3(SS)N0) was demonstrated in a multicenter, con-
trolled trial (JCOG 0703) (18), and a randomized, controlled trial
to compare long-term survival after LADG and open distal gastrec-
tomy for clinical stagecancers is ongoing in Japan (JCOG 0912)
(19), and the results are awaited. Recently, some surgeons have
been concerned about laparoscopic surgery for AGC (20). Since
Uyama et al. (21) reported laparoscopy-assisted total gastrectomy
with D2 lymph node dissection and distal pancreaticosplenectomy
for advanced upper- third gastric cancer, there have been several
studies to determine the technical feasibility of D2 lymph node
dissection in AGC. Gordon et al. (22) demonstrated that LDG with
D2 dissection for AGC was feasible and could match the survival
rate of open distal gastrectomy using a cohort in which 67.2% had
a tumor of stageB or higher with an average follow-up period of
49.2 months. Fukunaga et al. (23) reported that oncologic out-
comes were good in patients with T1N0-1 and T2N0 gastric can-
cer who underwent LADG with extended lymph node dissection.
Extended lymph node dissection has been reported in Japan and
Europe to improve outcomes of gastric cancer (24). However, the
use of laparoscopic surgery with extended lymph node dissection
for AGC still continues to be controversial because of the technical
difficulty of lymphadenectomy and the lack of data on the proce-
dure’s oncologic adequacy. Laparoscopic extended lymph node
dissection should be performed by an expert. In our hospital, the
operators are limited to experts who have passed an endoscopic
surgical skill qualification system (25). We have established the
procedure of D2 lymphadenectomy in LDG, which is needed for
standard surgery with AGC, so the eligibility criteria for LDG were
extended to cT3N1 gastric cancer.
With regard to accuracy, analysis of many cases of advanced can-
cer in which open surgery was performed have found that retrieval
of a sufficient number of lymph nodes is important to improve the
diagnostic accuracy and prognosis, and retrieval of 25 lymph nodes
is recommended in T2 (26). In the present study, 31.4 lymph nodes
were retrieved, which does not seem to be a problem in terms of
accuracy compared with open surgery.
With regard to safety, conversion to open surgery was done in
1 patient (1.0%) because of advanced stage disease, T4 depth, in
the present study. There were no specific complications attribut-
able to laparoscopic surgery.
Several studies presented mortality and morbidity data associ-
ated with laparoscopy-assisted gastrectomy. In the KLASS-trial
(27), the authors reported mortality of 1.1% and morbidity of 10.5%.
In the present study, there were 14 cases (15.3%) of postoperative
morbidity and no mortality. Complications that required reopera-
tion and intensive care, Clavien-Dindo classification gradea,
occurred in two cases. In one case, anastomotic leakage occurred
seven days after operation, and drainage was performed under la-
parotomy. In another case, a pancreatic fistula occurred that caused
secondary anastomotic leakage. There two cases finally recovered
and were discharged.
Several authors have shown no difference in recurrence or sur-
vival following laparoscopic surgery and open surgery for EGC.
However, in the case of AGC, the difference has remained contro-
versial. Recently, Song et al. (28) reported on their multicenter,
retrospective analysis of recurrence following laparoscopy-assisted
gastrectomy. They stated that the incidence of recurrence was
3.5% in all patients, 1.6% in EGC, and 13.4% in AGC. During the
present follow-up period, ten patients (10.9%) were found to have
tumor recurrence. They reported that the peritoneum and liver
were the most common recurrence sites. In the present study,
liver metastasis occurred in five patients (50.0%), which was the
most common recurrence site. There were no recurrences in re-
gional lymph nodes. Peritoneal dissemination occurred in four
patients (T3, one patient ; T4a, three patients), but there were no
cases with port site recurrences. Effects of pneumoperitoneum
manipulations on progression of the cancer and effects of the ma-
nipulation on tumor dissemination have been reported (29), so
Fig 2. Overall survival and disease - free survival
Kaplan-Meier overall survival (A) and disease - free survival (B) curves
according to tumor stage, based on the 7th edition of the TNM classifi-
cation. Stagedisease was omitted because of the small sample size.
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continued follow-up and are needed.
Kitano et al. (15) reported on the long-term outcomes of laparo-
scopic gastrectomy in a retrospective, multicenter study of laparo-
scopic gastrectomy for EGC that analyzed 1294 patients from 16
institutions. They reported that the 5-year DFS rates were 99.8%,
98.7%, and 85.7% for stagesA,B, and, respectively. In the case
of laparoscopic surgery for AGC, some authors reported their
short - term and long-term outcomes. Lee and Kim (30) presented
the long-term outcomes of AGC, with OS of 81.4% and DFS of
72.4%. In all of the present cases, the 5-year OS and DFS rates
were 76.8% and 72.6%, respectively.
This study has the drawbacks that there was no comparative
analysis with open gastrectomy, and the follow-up period was
short. For the elucidation of oncologic safety and clinical feasibil-
ity of laparoscopic distal gastrectomy for AGC, a comparative study
of short - term and long-term results with the open method will be
necessary. Although further study comparing laparoscopic distal
gastrectomy to open gastrectomy for AGC is needed, laparoscopic
distal gastrectomy with adequate lymph node dissection for AGC
appears to be an oncologically safe, feasible, and curative proce-
dure. A large-scale, randomized trial is needed to confirm the on-
cological safety and feasibility of laparoscopic distal gastrectomy
for patients with advanced gastric cancer.
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